This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Hepatitis
  • /
  • The Global Epidemiology of NAFLD and NASH in Patie...

The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis.

Read time: 1 mins
Published:4th Jul 2019
Author: Younossi ZM, Golabi P, de Avila L, Minhui Paik J, Srishord M, Fukui N et al.
Availability: Pay for access, or by subscription
Ref.:J Hepatol. 2019. pii: S0168-8278(19)30393-9.

Background and Aims: Although Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH) and NASH with advanced fibrosis are closely associated with type 2 diabetes mellitus (T2DM), their global prevalence rates have not been not well described. Our aim was to estimate the prevalence of NAFLD, NASH, and advanced fibrosis among T2DM patients by regions of the world.

Methods: PubMed, Ovid-Medline, EMBASE and Web of Science were searched from January 1989 to September 2018 for terms involving NAFLD, NASH, and T2DM. Strict exclusion criteria were applied. Regional and global mean prevalence weighted by population size in each country were estimated and pooled using random-effects meta-analysis. Potential sources of heterogeneity were investigated using stratified meta-analysis and meta-regression.

Results: Among 80 studies from 20 countries that met our inclusion criteria, there were 49,419 subjects with T2DM (mean age 58.5 years, mean BMI 27.9 kg/m2, and males 52.9%). The global prevalence of NAFLD among T2DM patients was 55.5% (95% CI: 47.3-63.7). Studies from Europe reported the highest prevalence (68.0% [62.1-73.0]).
Among 10 studies that estimated the prevalence of NASH, the global prevalence of NASH among subjects with T2DM was 37.3% (95% CI: 24.7-50.0). Seven studies estimated the prevalence of advanced fibrosis in patients with NAFLD and T2DM to be 17.0% (95% CI: 7.2-34.8). Meta-regression models showed that geographic region and mean age (p<.05) were associated with the prevalence of NAFLD, jointly accounting for 63.9% of the heterogeneity.

Conclusions: This study provides the global prevalence rates for NAFLD, NASH, and advanced fibrosis in patients with T2DM. These data can be used to estimate the clinical and economic burden of NASH in patients with T2DM around the world.


Read abstract on library site

Access full article